(A1)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

G00002

(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072832 A2

(51) International Patent Classification[7]: C12N 15/13, C07K 16/28, C12N 15/79, 15/10, A61K 39/395, A61P 37/00

(21) International Application Number: PCT/EP02/01420

(22) International Filing Date: 11 February 2002 (11.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0103389.3 12 February 2001 (12.02.2001) GB

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4055 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **AVERSA, Gregorio** [IT/AT]; trauttmansdorffgasse 11/7, A-1130 Vienna (AT). **KOLBINGER, Frank** [DE/DE]; Thuner Ring 4, 79395 Neuenburg (DE). **CARBALLIDO HERRERA, José, M.** [ES/AT]; Woebergasse 27, A-1235 Vienna (AT). **ASZÓDI, András** [HU/AT]; Bujattigasse 15B/19, A-1140 Vienna (AT). **SALDANHA, José, W.** [GB/GB]; 21 Fillebrook Avenue, Enfield, London EN1 3BD (GB). **HALL, Bruce, M.** [AU/AU]; 14 Vernon Street, Strathfield, NSW 2135 (AU).

(74) Agent: **BECKER, Konrad**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

162162

WO 02/072832 A2

(54) Title: THERAPEUTIC BINDING MOLECULES

(57) Abstract: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid seuqnce Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1', CDR2' and CDR3', CDR1' having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln 8RASQNIGTSIQ), CDR', having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3' having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chmieric or humanised antibody, useful as a pharmaceutical.